Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Colorectal Neoplasms

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 70 articles:
HTML format
Text format



Single Articles


    February 2017
  1. WENG W, Wei Q, Toden S, Yoshida K, et al
    Circular RNA ciRS-7 - A promising prognostic biomarker and a potential therapeutic target in colorectal cancer.
    Clin Cancer Res. 2017 Feb 7. pii: clincanres.2541.2016.
    PubMed     Text format     Abstract available


    January 2017
  2. GOVERNA V, Trella E, Mele V, Tornillo L, et al
    The interplay between neutrophils and CD8+ T cells improves survival in human colorectal cancer.
    Clin Cancer Res. 2017 Jan 20. pii: clincanres.2047.2016.
    PubMed     Text format     Abstract available


    November 2016
  3. BLAJ C, Bringmann A, Schmidt EM, Urbischek M, et al
    ADNP is a therapeutically inducible repressor of WNT signaling in colorectal cancer.
    Clin Cancer Res. 2016 Nov 30. pii: clincanres.1604.2016.
    PubMed     Text format     Abstract available


  4. SUMMERS M, Smith CG, Maughan TS, Kaplan R, et al
    BRAF and NRAS locus specific variants have different outcomes on survival to colorectal cancer.
    Clin Cancer Res. 2016 Nov 4. pii: clincanres.1541.2016.
    PubMed     Text format     Abstract available


    October 2016
  5. PIETRANTONIO F, Vernieri C, Siravegna G, Mennitto A, et al
    Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer.
    Clin Cancer Res. 2016 Oct 25. pii: clincanres.1863.2016.
    PubMed     Text format     Abstract available


  6. LIANG JQ, Chiu J, Chen Y, Huang Y, et al
    Fecal Bacteria Act as Novel Biomarkers for Non-Invasive Diagnosis of Colorectal Cancer.
    Clin Cancer Res. 2016 Oct 3. pii: clincanres.1599.2016.
    PubMed     Text format     Abstract available


  7. NEGRI FV, Boggiani D, Rimanti A, Musolino A, et al
    FCGR, Cetuximab, and Colorectal Cancer Survival-Letter.
    Clin Cancer Res. 2016;22:4958.
    PubMed     Text format    


    September 2016
  8. MA Y, Wang L, Neitzel LR, Loganathan S, et al
    The MAPK pathway regulates intrinsic resistance to BET inhibitors in colorectal cancer.
    Clin Cancer Res. 2016 Sep 27. pii: clincanres.0453.2016.
    PubMed     Text format     Abstract available


  9. PARK JH, Van Wyk HC, McMillan DC, Quinn JA, et al
    Signal transduction and activator of transcription-3 (STAT3) in patients with colorectal cancer: associations with the phenotypic features of the tumour and host.
    Clin Cancer Res. 2016 Sep 27. pii: clincanres.1416.2016.
    PubMed     Text format     Abstract available


  10. SALVUCCI M, Wurstle ML, Morgan C, Curry S, et al
    A stepwise integrated approach to personalized risk predictions in stage III colorectal cancer.
    Clin Cancer Res. 2016 Sep 20. pii: clincanres.1084.2016.
    PubMed     Text format     Abstract available


    August 2016
  11. SHIGEYASU K, Okugawa Y, Toden S, Boland CR, et al
    Exportin-5 functions as an oncogene and a potential therapeutic target in colorectal cancer.
    Clin Cancer Res. 2016 Aug 23. pii: clincanres.1023.2016.
    PubMed     Text format     Abstract available


  12. WEI TT, Lin YT, Tseng RY, Shun CT, et al
    Prevention of Colitis and Colitis-Associated Colorectal Cancer by a Novel Polypharmacological Histone Deacetylase Inhibitor.
    Clin Cancer Res. 2016;22:4158-69.
    PubMed     Text format     Abstract available


  13. TOFFOLI G, Sharma MR, Marangon E, Posocco B, et al
    Genotype-guided dosing study of FOLFIRI plus bevacizumab in metastatic colorectal cancer patients.
    Clin Cancer Res. 2016 Aug 9. pii: clincanres.1012.2016.
    PubMed     Text format     Abstract available


  14. YAMAMOTO T, Kawada K, Itatani Y, Inamoto S, et al
    Loss of SMAD4 Promotes Lung Metastasis of Colorectal Cancer by Accumulation of CCR1+ Tumor-associated Neutrophils through CCL15-CCR1 Axis.
    Clin Cancer Res. 2016 Aug 4. pii: clincanres.0520.2016.
    PubMed     Text format     Abstract available


  15. MUSTAFI R, Dougherty U, Mustafi D, Ayaloglu-Butun F, et al
    ADAM17 is a tumor promoter and therapeutic target in Western diet-associated colon cancer.
    Clin Cancer Res. 2016 Aug 3. pii: clincanres.3140.2016.
    PubMed     Text format     Abstract available



  16. Correction: MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
    Clin Cancer Res. 2016;22:3982.
    PubMed     Text format    


    July 2016
  17. TRINH A, Trumpi K, de Sousa E Melo F, Wang X, et al
    Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry.
    Clin Cancer Res. 2016 Jul 26. pii: clincanres.0680.2016.
    PubMed     Text format     Abstract available


  18. QIAN DC, Xiao X, Byun J, Suriawinata AA, et al
    PI3K/Akt/mTOR signaling and plasma membrane proteins are implicated in responsiveness to adjuvant dendritic cell vaccination for metastatic colorectal cancer.
    Clin Cancer Res. 2016 Jul 19. pii: clincanres.0623.2016.
    PubMed     Text format     Abstract available


  19. DE ROBERTIS M, Loiacono L, Fusilli C, Poeta LM, et al
    Dysregulation of EGFR pathway in EphA2 cell subpopulation significantly associates with poor prognosis in colorectal cancer.
    Clin Cancer Res. 2016 Jul 11. pii: clincanres.0709.2016.
    PubMed     Text format     Abstract available


  20. BENSON AB, Kiss I, Bridgewater J, Eskens FA, et al
    BATON-CRC: a phase II randomized trial comparing tivozanib plus mFOLFOX6 with bevacizumab plus mFOLFOX6 in stage IV metastatic colorectal cancer.
    Clin Cancer Res. 2016 Jul 11. pii: clincanres.3117.2016.
    PubMed     Text format     Abstract available


    June 2016
  21. BARRAS D, Missiaglia E, Wirapati P, Sieber OM, et al
    BRAF V600E mutant colorectal cancer subtypes based on gene expression.
    Clin Cancer Res. 2016 Jun 27. pii: clincanres.0140.2016.
    PubMed     Text format     Abstract available


  22. KUROIWA-TRZMIELINA J, Wang F, Rapkins RW, Ward RL, et al
    SNP rs16906252C>T is an expression and methylation quantitative trait locus associated with an increased risk of developing MGMT-methylated colorectal cancer.
    Clin Cancer Res. 2016 Jun 7. pii: clincanres.2765.2015.
    PubMed     Text format     Abstract available


    May 2016
  23. LIU G, Tu D, Lewis M, Cheng D, et al
    Fc-gamma Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer.
    Clin Cancer Res. 2016;22:2435-44.
    PubMed     Text format     Abstract available


  24. MUNAKATA K, Uemura M, Tanaka S, Kawai K, et al
    Cancer stem-like properties in colorectal cancer cells with low proteasome activity.
    Clin Cancer Res. 2016 May 10. pii: clincanres.1945.2015.
    PubMed     Text format     Abstract available


  25. WENG W, Okugawa Y, Toden S, Toiyama Y, et al
    FOXM1 and FOXQ1 are promising prognostic biomarkers and novel targets of tumor suppressive miR-342 in human colorectal cancer.
    Clin Cancer Res. 2016 May 9. pii: clincanres.0360.2016.
    PubMed     Text format     Abstract available


  26. DUNNE PD, McArt DG, Bradley CA, O'Reilly PG, et al
    Challenging the cancer molecular stratification dogma: Intratumoral heterogeneity undermines consensus molecular subtypes and potential diagnostic value in colorectal cancer.
    Clin Cancer Res. 2016 May 5. pii: clincanres.0032.2016.
    PubMed     Text format     Abstract available


  27. BARTOLINI A, Cardaci S, Lamba S, Oddo D, et al
    BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS Mutant Colorectal Cancer.
    Clin Cancer Res. 2016 May 3. pii: clincanres.2664.2015.
    PubMed     Text format     Abstract available


    April 2016
  28. CIARLONI L, Hosseinian Ehrensberger S, Imaizumi N, Monnier-Benoit S, et al
    Development and clinical validation of a blood test based on 29-gene expression for early detection of colorectal cancer.
    Clin Cancer Res. 2016 Apr 28. pii: clincanres.2057.2015.
    PubMed     Text format     Abstract available


  29. BOSCH LJ, Luo Y, Valinluck Lao V, Snaebjornsson P, et al
    WRN promoter CpG island hypermethylation does not predict more favorable outcomes for metastatic colorectal cancer patients treated with irinotecan-based therapy.
    Clin Cancer Res. 2016 Apr 27. pii: clincanres.2703.2015.
    PubMed     Text format     Abstract available


  30. MEYN RE, Krishnan S, Skinner HD
    Everything Old Is New Again: Using Nelfinavir to Radiosensitize Rectal Cancer.
    Clin Cancer Res. 2016;22:1834-6.
    PubMed     Text format     Abstract available


  31. HILL EJ, Roberts C, Franklin JM, Enescu M, et al
    Clinical Trial of Oral Nelfinavir before and during Radiation Therapy for Advanced Rectal Cancer.
    Clin Cancer Res. 2016;22:1922-31.
    PubMed     Text format     Abstract available


  32. FERREIRO-NEIRA I, Torres NE, Liesenfeld LF, Chan CH, et al
    XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal Cancer.
    Clin Cancer Res. 2016;22:1663-73.
    PubMed     Text format     Abstract available


    March 2016
  33. GHOSH P, Tie J, Muranyi A, Singh S, et al
    Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair Proficient Stage II Colon Cancer.
    Clin Cancer Res. 2016 Mar 30. pii: clincanres.2290.2015.
    PubMed     Text format     Abstract available


  34. BECHT E, de Reynies A, Giraldo NA, Pilati C, et al
    Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy.
    Clin Cancer Res. 2016 Mar 18. pii: clincanres.2879.2015.
    PubMed     Text format     Abstract available


  35. MIMA K, Nishihara R, Yang J, Dou R, et al
    MicroRNA <i>MIR21</i> (miR-21) and PTGS2 expression in colorectal cancer and patient survival.
    Clin Cancer Res. 2016 Mar 8. pii: clincanres.2173.2015.
    PubMed     Text format     Abstract available


    February 2016
  36. SANCHEZ-MARTIN FJ, Bellosillo B, Gelabert M, Dalmases A, et al
    The first-in-class anti-EGFR antibody mixture Sym004 overcomes cetuximab-resistance mediated by EGFR extracellular domain mutations in colorectal cancer.
    Clin Cancer Res. 2016 Feb 17. pii: clincanres.2400.2015.
    PubMed     Text format     Abstract available


  37. DUDLEY JC, Lin MT, Le DT, Eshleman JR, et al
    Microsatellite Instability as a Biomarker for PD-1 Blockade.
    Clin Cancer Res. 2016;22:813-20.
    PubMed     Text format     Abstract available


  38. MEULENDIJKS D, Jacob W, Martinez-Garcia M, Taus A, et al
    First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors.
    Clin Cancer Res. 2016;22:877-85.
    PubMed     Text format     Abstract available


  39. PATNAIK A, Weiss GJ, Leonard JE, Rasco DW, et al
    Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors.
    Clin Cancer Res. 2016;22:827-36.
    PubMed     Text format     Abstract available


  40. MEULENDIJKS D, Lassen UN, Siu LL, Huitema AD, et al
    Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors.
    Clin Cancer Res. 2016;22:858-67.
    PubMed     Text format     Abstract available


  41. YAN P, Klingbiel D, Saridaki Z, Ceppa P, et al
    REDUCED EXPRESSION OF SMAD4 IS ASSOCIATED WITH POOR SURVIVAL IN COLON CANCER.
    Clin Cancer Res. 2016 Feb 9. pii: clincanres.0939.2015.
    PubMed     Text format     Abstract available


  42. MORITA R, Hirohashi Y, Torigoe T, Inoda S, et al
    Olfactory receptor family receptor, family 7, subfamily C, member 1 is a novel marker of colon cancer-initiating cells and is a potent target of immunotherapy.
    Clin Cancer Res. 2016 Feb 9. pii: clincanres.1709.2015.
    PubMed     Text format     Abstract available


  43. EL MESSAOUDI S, Mouliere F, Du Manoir S, Bascoul-Mollevi C, et al
    Circulating DNA as a strong multi-marker prognostic tool for metastatic colorectal cancer patient management care.
    Clin Cancer Res. 2016 Feb 4. pii: clincanres.0297.2015.
    PubMed     Text format     Abstract available


  44. MATSUSAKA S, Hanna DL, Cao S, Zhang W, et al
    Prognostic Impact of IL-6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy.
    Clin Cancer Res. 2016 Feb 2. pii: clincanres.2422.2015.
    PubMed     Text format     Abstract available


  45. YAMAMOTO H, Murata K, Fukunaga M, Ohnishi T, et al
    Micrometastasis Volume in Lymph Nodes Determines Disease Recurrence Rate of Stage II Colorectal Cancer: A Prospective Multicenter Trial.
    Clin Cancer Res. 2016 Feb 1. pii: clincanres.2199.2015.
    PubMed     Text format     Abstract available


  46. VUCKOVIC F, Theodoratou E, Thaci K, Timofeeva M, et al
    IgG glycome in colorectal cancer.
    Clin Cancer Res. 2016 Feb 1. pii: clincanres.1867.2015.
    PubMed     Text format     Abstract available


  47. SCHELL MJ, Yang M, Missiaglia E, Delorenzi M, et al
    A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome.
    Clin Cancer Res. 2016;22:734-45.
    PubMed     Text format     Abstract available


  48. XU L, Ziegelbauer J, Wang R, Wu WW, et al
    Distinct Profiles for Mitochondrial t-RNAs and Small Nucleolar RNAs in Locally Invasive and Metastatic Colorectal Cancer.
    Clin Cancer Res. 2016;22:773-84.
    PubMed     Text format     Abstract available


  49. ARQUES O, Chicote I, Puig I, Tenbaum SP, et al
    Tankyrase Inhibition Blocks Wnt/beta-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
    Clin Cancer Res. 2016;22:644-56.
    PubMed     Text format     Abstract available


    January 2016
  50. ZIEMKE EK, Dosch JS, Maust JD, Shettigar A, et al
    Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.
    Clin Cancer Res. 2016;22:405-14.
    PubMed     Text format     Abstract available


  51. TURKSMA AW, Coupe VM, Shamier MC, Lam KL, et al
    Extent and Location of Tumor-Infiltrating Lymphocytes in Microsatellite-Stable Colon Cancer Predict Outcome to Adjuvant Active Specific Immunotherapy.
    Clin Cancer Res. 2016;22:346-56.
    PubMed     Text format     Abstract available


  52. INAMOTO S, Itatani Y, Yamamoto T, Minamiguchi S, et al
    Loss of SMAD4 Promotes Colorectal Cancer Progression by Accumulation of Myeloid-Derived Suppressor Cells through the CCL15-CCR1 Chemokine Axis.
    Clin Cancer Res. 2016;22:492-501.
    PubMed     Text format     Abstract available


  53. LEMOS C, Hardt MS, Juneja M, Voss C, et al
    MACC1 induces tumor progression in transgenic mice and colorectal cancer patients via increased pluripotency markers Nanog and Oct4.
    Clin Cancer Res. 2016 Jan 12. pii: clincanres.1425.2015.
    PubMed     Text format     Abstract available


  54. BALACHANDRAN VP, Arora A, Gonen M, Ito H, et al
    A validated prognostic multigene expression assay for overall survival in resected colorectal cancer liver metastases.
    Clin Cancer Res. 2016 Jan 5. pii: clincanres.1071.2015.
    PubMed     Text format     Abstract available


    December 2015
  55. ROLFF HC, Christensen IJ, Vainer B, Svendsen LB, et al
    The prognostic and predictive value of soluble of type IV collagen in colorectal cancer: A retrospective multicenter study.
    Clin Cancer Res. 2015 Dec 16. pii: clincanres.2342.2015.
    PubMed     Text format     Abstract available


    November 2015
  56. WERNER S, Krause F, Rolny V, Strobl M, et al
    Evaluation of a 5-Marker Blood Test for Colorectal Cancer Early Detection in a Colorectal Cancer Screening Setting.
    Clin Cancer Res. 2015 Nov 11. pii: clincanres.1268.2015.
    PubMed     Text format     Abstract available


  57. NYGARD SB, Vainer B, Nielsen SL, Bosman FT, et al
    DNA topoisomerase I gene copy number and mRNA expression assessed as predictive biomarkers for adjuvant irinotecan in stage II/III colon cancer.
    Clin Cancer Res. 2015 Nov 5. pii: clincanres.0561.2015.
    PubMed     Text format     Abstract available


  58. MUR P, Aiza G, Sanz-Pamplona R, Gonzalez S, et al
    AMER1 Is a Frequently Mutated Gene in Colorectal Cancer-Letter.
    Clin Cancer Res. 2015;21:4985.
    PubMed     Text format    


    October 2015
  59. WANG X, Zhang C, Yan X, Lan B, et al
    A novel bioavailable BH3 mimetic efficiently inhibits colon cancer via cascade effects of mitochondria.
    Clin Cancer Res. 2015 Oct 29. pii: clincanres.0732.2015.
    PubMed     Text format     Abstract available


    May 2015
  60. LOLKEMA MP, Bohets HH, Arkenau HT, Lampo A, et al
    The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation.
    Clin Cancer Res. 2015;21:2297-304.
    PubMed     Text format     Abstract available


    April 2015
  61. BOHANES P, Rankin CJ, Blanke CD, Winder T, et al
    Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation.
    Clin Cancer Res. 2015;21:1583-90.
    PubMed     Text format     Abstract available


  62. GALA MK, Chan AT
    Molecular pathways: aspirin and Wnt signaling-a molecularly targeted approach to cancer prevention and treatment.
    Clin Cancer Res. 2015;21:1543-8.
    PubMed     Text format     Abstract available


    March 2015
  63. BAUMER S, Baumer N, Appel N, Terheyden L, et al
    Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer.
    Clin Cancer Res. 2015;21:1383-94.
    PubMed     Text format     Abstract available


  64. YAEGER R, Cercek A, O'Reilly EM, Reidy DL, et al
    Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.
    Clin Cancer Res. 2015;21:1313-20.
    PubMed     Text format     Abstract available


  65. SHEN Y, Ma J, Yan R, Ling H, et al
    Impaired self-renewal and increased colitis and dysplastic lesions in colonic mucosa of AKR1B8-deficient mice.
    Clin Cancer Res. 2015;21:1466-76.
    PubMed     Text format     Abstract available


  66. LIANG B, Shahbaz M, Wang Y, Gao H, et al
    Integrinbeta6-targeted immunoliposomes mediate tumor-specific drug delivery and enhance therapeutic efficacy in colon carcinoma.
    Clin Cancer Res. 2015;21:1183-95.
    PubMed     Text format     Abstract available


  67. ZHANG X, Yang X, Zhang Y, Liu X, et al
    Direct serum assay for cell-free bmi-1 mRNA and its potential diagnostic and prognostic value for colorectal cancer.
    Clin Cancer Res. 2015;21:1225-33.
    PubMed     Text format     Abstract available


  68. CUSHMAN SM, Jiang C, Hatch AJ, Shterev I, et al
    Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
    Clin Cancer Res. 2015;21:1078-86.
    PubMed     Text format     Abstract available


  69. LAURENT-PUIG P, Pekin D, Normand C, Kotsopoulos SK, et al
    Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy.
    Clin Cancer Res. 2015;21:1087-97.
    PubMed     Text format     Abstract available


    February 2015
  70. SATELLI A, Mitra A, Brownlee Z, Xia X, et al
    Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression.
    Clin Cancer Res. 2015;21:899-906.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: